
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareholder value Day One’s OJEMDA™ (tovorafenib) and Zevra’s …